Status:
UNKNOWN
Carbetocin Versus Misoprostol in Cases With Placenta Previa After C.S.
Lead Sponsor:
Beni-Suef University
Collaborating Sponsors:
Cairo University
Conditions:
Postpartum Hemorrhage
Eligibility:
FEMALE
25-40 years
Phase:
PHASE4
Brief Summary
We will compare efficacy and safety of Carbetocin with Misoprostol in prevention of postpartum hemorrhage in Placenta previa women after C.S.
Detailed Description
Postpartum hemorrhage was traditionally defined as blood loss in excess of 500 mL from a vaginal delivery or 1000 mL at cesarean section. It can result from uterine atony, retained placental tissue in...
Eligibility Criteria
Inclusion
- Women with a singleton pregnancy undergoing cesarean section after 37 weeks of gestation.
Exclusion
- • Women undergoing caesarean section with general anesthesia will be excluded, because carbetocin is licensed for use with regional anaesthesia only.
- women undergoing caesarean section at less than 37 weeks of gestation.
- Hypertension with pregnancy.
- Cardiac and coronary diseases with pregnancy
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT02277041
Start Date
October 1 2014
End Date
April 1 2021
Last Update
February 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beni-Suef University
Cairo, Egypt